News & Updates

Prior ICI therapy potentially improves COVID-19 outcomes in cancer patients

01 Dec 2023

Previous exposure to immune checkpoint inhibitors (ICIs) does not appear to worsen COVID-19 outcomes but may even improve them in patients with cancer, according to a study.

Prior ICI therapy potentially improves COVID-19 outcomes in cancer patients

01 Dec 2023

Novel microbiome technology boosts Clostridioides difficile cure rate to >90 percent

01 Dec 2023 by

A novel microbiome technology developed by researchers at the Chinese University of Hong Kong (CUHK) enhances faecal microbiota transplantation (FMT) success rate to >90 percent in patients with recurrent Clostridioides difficile infection (CDI). FMT with the novel technology will become available in public hospitals in Hong Kong.

Novel microbiome technology boosts Clostridioides difficile cure rate to >90 percent

01 Dec 2023

NIH updates: Remdesivir recommended for patients hospitalized for COVID-19

01 Dec 2023

Remdesivir is recommended for hospitalized patients with COVID-19, according to latest updates of the US National Institutes of Health (NIH) guidelines issued on 10^th October 2023.

NIH updates: Remdesivir recommended for patients hospitalized for COVID-19

01 Dec 2023

Hepatocellular carcinoma risk diminishes with time following HCV eradication

30 Nov 2023

Among individuals with cirrhosis and cured hepatitis C virus (HCV) infection, the risk of hepatocellular carcinoma tapers off progressively through 6 years after HCV eradication, as shown in a study. However, the risk remains above thresholds that require screening.

Hepatocellular carcinoma risk diminishes with time following HCV eradication

30 Nov 2023

COVID-19 infection ups CV risk in people living with HIV

29 Nov 2023 by

People living with HIV (PLWH) who were diagnosed with COVID-19 had a 35-percent higher risk of a major cardiovascular (CV) event in the following year than PLWH without COVID in a Spanish study.

COVID-19 infection ups CV risk in people living with HIV

29 Nov 2023

PIBIK: Switching to B/F/TAF maintains HIV suppression through 48 weeks

28 Nov 2023 by

Viral suppression is maintained through 48 weeks in adults with HIV-1 harbouring drug resistance mutations, who switched to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) fixed-dose combination pill from a boosted protease inhibitor (bPI) therapy, according to recent data from the phase IV open-label PIBIK trial.

PIBIK: Switching to B/F/TAF maintains HIV suppression through 48 weeks

28 Nov 2023

HRV/EV infections affect the respiratory system, yield low mortality rates

28 Nov 2023

The respiratory system is the main target of human rhinovirus/enterovirus (HRV/EV) infections, which show a clinical course with low mortality rates, reveals a study.

HRV/EV infections affect the respiratory system, yield low mortality rates

28 Nov 2023

Convalescent plasma cuts death in mechanically ventilated patients with COVID-19-induced ARDS

28 Nov 2023 by

In the CONFIDENT trial, convalescent plasma (CCP) conferred a mortality benefit for patients with COVID-19-induced acute respiratory distress syndrome (ARDS) who were on invasive mechanical ventilation (IMV).

Convalescent plasma cuts death in mechanically ventilated patients with COVID-19-induced ARDS

28 Nov 2023

Do children with HRV/EV fare better than those with other respiratory viruses?

27 Nov 2023

Children who test positive for human rhinovirus/enterovirus (HRV/EV) require close monitoring by clinicians, given possible clinical outcomes that are either similar or worse than known highly pathogenic viruses, suggests a recent study.

Do children with HRV/EV fare better than those with other respiratory viruses?

27 Nov 2023

Palliative care in cancer: Which central venous access devices are associated with higher complication rates?

27 Nov 2023 by

A systematic review and meta-analysis by researchers from the University of Hong Kong has shown that the use of peripherally inserted central catheters (PICCs) is associated with a higher rate of complications than central lines in terminally ill cancer patients with central venous access devices (CVADs) for palliative care. No conclusions were reached regarding the use of totally implanted ports (PORTs), as no studies on PORTs were eligible for analysis.

Palliative care in cancer: Which central venous access devices are associated with higher complication rates?

27 Nov 2023

News & Updates

Filter by Specialty:

Specialty:

Prior ICI therapy potentially improves COVID-19 outcomes in cancer patients

Prior ICI therapy potentially improves COVID-19 outcomes in cancer patients

Novel microbiome technology boosts Clostridioides difficile cure rate to >90 percent

Novel microbiome technology boosts Clostridioides difficile cure rate to >90 percent

NIH updates: Remdesivir recommended for patients hospitalized for COVID-19

NIH updates: Remdesivir recommended for patients hospitalized for COVID-19

Hepatocellular carcinoma risk diminishes with time following HCV eradication

Hepatocellular carcinoma risk diminishes with time following HCV eradication

COVID-19 infection ups CV risk in people living with HIV

COVID-19 infection ups CV risk in people living with HIV

PIBIK: Switching to B/F/TAF maintains HIV suppression through 48 weeks

PIBIK: Switching to B/F/TAF maintains HIV suppression through 48 weeks

HRV/EV infections affect the respiratory system, yield low mortality rates

HRV/EV infections affect the respiratory system, yield low mortality rates

Convalescent plasma cuts death in mechanically ventilated patients with COVID-19-induced ARDS

Convalescent plasma cuts death in mechanically ventilated patients with COVID-19-induced ARDS

Do children with HRV/EV fare better than those with other respiratory viruses?

Do children with HRV/EV fare better than those with other respiratory viruses?

Palliative care in cancer: Which central venous access devices are associated with higher complication rates?

Palliative care in cancer: Which central venous access devices are associated with higher complication rates?